e-learning
resources
Berlin 2008
Sunday, 05.10.2008
Infectious lung diseases including tuberculosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The risk of community-acquired pneumonia and the use of statins, ACE inhibitors and gastric acid suppressants
P. Myles, T. McKeever, Z. Hoare, C. Smith, R. Hubbard (Nottingham, United Kingdom)
Source:
Annual Congress 2008 - Infectious lung diseases including tuberculosis
Session:
Infectious lung diseases including tuberculosis
Session type:
Thematic Poster Session
Number:
611
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Myles, T. McKeever, Z. Hoare, C. Smith, R. Hubbard (Nottingham, United Kingdom). The risk of community-acquired pneumonia and the use of statins, ACE inhibitors and gastric acid suppressants. Eur Respir J 2008; 32: Suppl. 52, 611
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Microbial evaluation of proton-pump inhibitors and the risk of pneumonia
Source: Eur Respir J 2011; 38: 1165-1172
Year: 2011
The risk of community-acquired pneumonia in children using gastric acid suppressants
Source: Eur Respir J, 58 (4) 2003229; 10.1183/13993003.03229-2020
Year: 2021
Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia
Source: Eur Respir J 2008; 31: 611-617
Year: 2008
Inhaled drugs as risk factors for community-acquired pneumonia
Source: Eur Respir J 2010; 36: 1080-1087
Year: 2010
Correlation between the use of statins and ACE inhibitors with the length of hospitalization for COPD exacerbations
Source: Annual Congress 2010 - COPD: treatment and monitoring
Year: 2010
Inhaled drugs as risk factors for community-acquired pneumonia
Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools
Year: 2010
Angiotensin-converting enzyme insertion/deletion polymorphism and risk and outcome of pneumonia
Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia
Year: 2007
Combination versus monotherapy for nosocomial pneumonia
Source: Eur Respir Rev 2007; 16: 50-55
Year: 2007
Influence of prior nonsteroidal anti-inflammatory steroidal drugs (NSAID) on the presentation and evolution of hospitalized community-acquired pneumonia
Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management
Year: 2015
Non-steroidal anti-inflammatory drug use and clinical outcomes of community-acquired pneumonia
Source: International Congress 2018 – Improving the outcomes of community-acquired pneumonia
Year: 2018
ACE inhibitors prevent aspiration pneumonia in Asian, but not Caucasian, elderly patients with stroke
Source: Eur Respir J 2007; 29: 218-219
Year: 2007
Are statins beneficial for viral pneumonia?
Source: Eur Respir J 2013; 41: 1010-1011
Year: 2013
Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients
Source: Eur Respir J 2015; 45: 463-472
Year: 2015
Are corticosteroids useful in community-acquired pneumonia?
Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia
Year: 2006
Active monitoring of adverse drug reactions to the use of beta-lactam antibiotics in the treatment of community-acquired pneumonia
Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections
Year: 2020
Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia
Source: Eur Respir J 2009; 33: 153-159
Year: 2009
Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia
Source: Eur Respir J 2011; 37: 1332-1339
Year: 2011
The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 733s
Year: 2006
Associations of aspirin, statins and metformin with lung cancer risk and related mortality
Source: Breathe, 17 (2) 200325; 10.1183/20734735.0325-2020
Year: 2021
Statin therapy and reduced risk of pneumonia in elderly patients with diabetes
Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept